Skip to content

Inventories at other companies

AbbVie logo
AbbVieABBV
$5.05B+11.6%
Bausch + Lomb logo
Bausch + LombBLCO
$977M-5.2%
Warby Parker logo
Warby ParkerWRBY
$46.45M-4.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$3.1B-2.8%
Glaukos logo
GlaukosGKOS
$62.38M+4.9%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryNoncurrent.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s inventories?
Tarsus Pharmaceuticals, Inc. (TARS) reported inventories of $2.53M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s inventories changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s inventories decreased by 0.2% year-over-year, from $2.53M to $2.53M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.